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Hepatitis B virus (HBV) integration in hepatocellular carcinoma (HCC) is a poorly understood event. In a recent
Cancer Cell paper, Lau et al. (2014) describe a HBV-human fusion transcript (HBx-LINE1) that functions as a
lncRNA, influences the epithelial-mesenchymal transition, and correlates with reduced patient survival and
tumor formation in mice.Hepatocellular carcinoma (HCC) is the
most frequent primary liver cancer and
the fifth-most common cause of cancer-
related deaths in humans. HCC can be
induced by several etiologies including
alcohol or drug abuse, inflammatory liver
disease, and a high-fat or high-sugar
diet. The most relevant etiology driving
liver cancer, however, is chronic infection
with hepatitis C or B viruses (HCV; HBV).
Worldwide, approximately 240 million
people are chronically infected with
HBV, and chronic HBV carriers are at
high risk for developing cancer (El-Serag
and Rudolph, 2007). In most cases,
chronic HBV infection induces chronic
liver inflammation and liver injury, which
drives the development of liver fibrosis
and subsequent cirrhosis, ultimately lead-
ing to HCC. Several epidemiologic and
experimental studies have indicated that
expression of HBV-derived proteins can
directly promote HCC formation—even
in the absence of chronic liver injury (Na
et al., 2011; Murakami et al., 2005). In
addition, HBV integration into the host
genome has been linked to liver cancer
formation (Matsubara and Tokino, 1990),
since 85%–90% of HBV-associated
HCCs contain at least one HBV integra-
tion site (Bre´chot et al., 2000). Initially, it
was proposed that HBV integrations
occur randomly without preferred in-
tegration sites. However, recent high-
throughput next-generation sequencing
studies identified recurrent insertion sites
with many HBV integrations occurring
within or near-repetitive, noncoding
sequences, such as LINEs (long inter-
spersed nuclear elements), SINEs (short
interspersed nuclear elements), and Alu
(named after the restriction enzyme
derived from the bacterium Arthrobacter
luteus, specifically cutting those se-
quences) (Ding et al., 2012). LINE andSINE are retrotransposons, making up
17% and 11% of the human genome,
respectively.
By applying an algorithm (ViralFusion-
Seq) enabling efficient and unbiased
detection of possible fusions between
viral and human sequences (Li et al.,
2013), Lau et al. (2014) describe the exis-
tence of a viral-human hybrid RNA. Start-
ing with HBV-positive HCC cell lines, the
authors identified a LINE(1) sequence
that was cotranscribed from an HBV
insertion detected in chr.8p11. This
LINE(1)-rich region of chromosome 8 is
placed within a transcriptionally silent het-
erochromatin containing no transcription
factor binding sites. The transcript identi-
fied turned out to be a fusion of the human
LINE(1) and the HBV encoded X protein
(HBx-LINE11-674 further denoted as HBx-
LINE[1]) transcripts, presumably being
driven by the HBx promoter (Figure 1).
HBx-LINE(1) transcription was detected
in 23.3% of the examined HCCs, corre-
lating with a shorter overall survival of
HCC patients.
In a series of well-conducted and
controlled in vitro experiments, Lau et al.
(2014) show that HBx-LINE(1) expression
results in a long noncoding (lnc) RNA that
drivesmigration and invasion of tumor cell
lines through the induction of epithelial-
mesenchymal transition (EMT) (Figure 1).
In order to determine whether the virally
encoded part, the human sequence, or
the full-length HBx-LINE(1) determines
the described functionality, the full-length
HBx-LINE11-674 and several variants were
expressed and investigated for their
biological effects. The authors demon-
strate that exclusively the full-length
HBVx-LINE(1) induces EMT and nuclear
translocation of b-catenin. To confirm
that the observed phenotype stemmed
from the HBx-LINE(1) mRNA and not pro-Cell Host & Microbe 1tein expression, Lau et al. (2014) intro-
duced a stop codon in the HBx-LINE(1)
RNA at the beginning of the HBx encoded
sequence, inhibiting protein translation
but still enabling transcription of the
HBx-LINE(1) fusion mRNA. Unambigu-
ously, the authors show that colony for-
mation, cell migration, and induction of
EMT depend on mRNA function and not
protein expression of HBx-LINE(1). Addi-
tionally, the authors ruled out the contri-
bution of potential microRNAs generated
from HBx-LINE(1). In vitro experiments
using Drosha and Dicer, which are essen-
tial formicroRNA production, showed that
there was no cleavage of full-length HBx-
LINE(1) into smaller 18–22 nt fragments,
suggesting a lack of hairpin folding of
HBx-LINE(1) to allow microRNA matura-
tion. Thus, the biological activity of full-
length HBx-LINE(1) is very likely mediated
as a lncRNA and not as a microRNA.
Finally, the authors show that expres-
sion of HBx-LINE(1) as a transgene in
livers of mice increases the incidence
and number of HCCs after treatment
with the chemical carcinogen diethyl-
nitrosamine (DEN). They also observed
enhanced nuclear b-catenin localization
in livers and HCC nodules in HBx-
LINE(1) transgenic mice. Although these
data suggest a role of HBx-LINE(1)
mRNA expression in DEN-induced liver
cancer formation, it would be interesting
to learn whether HCC in HBx-LINE(1)
transgenic mice differ from those of
control mice in terms of growth pattern
and transcriptional/genomic profile, and
whether comparable profiles are found
in HCC of patients with HBx-LINE(1)
mRNA expression.
As indicated by in situ experiments with
livers of HBx-LINE(1) transgenic mice,
high HBx-LINE1 mRNA expression is
exclusively found in DEN-induced HCC5, March 12, 2014 ª2014 Elsevier Inc. 249
Figure 1. Biological Consequences of HBx-LINE1 Expression
Schematic drawing of the HBx-LINE1 mRNA and its biological effects as a lncRNA on epithelial-mesen-
chymal transition (EMT) transition, nuclear b-catenin translocation, as well as HCC development in human
patients and diethyl-nitrosamine (DEN)-treated HBx-LINE1 transgenic mice.
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transgenic liver. Thus, it appears that
HBx-LINE1 reaches high expression
levels and exerts it biological effects
exclusively in an oncogenic environment.
Since presumably expression of HBx-
LINE(1) alone does not result in liver
damage or induce liver cancer, what are
the cofactors contributing to HBV-associ-
ated HCC development in humans?
Accordingly, it will be important to investi-
gate the underlying mechanisms of HBx-
LINE(1) RNA activity in an environmental
context. Along these lines, it will be equally
important to see if HBx-LINE(1) transcripts
can exert protumorigenic functions in
HCC mouse models with chronic inflam-
mation (Wolf et al., 2010)—as found in
most chronic HBV carriers.
Finally, it will be important to identify the
underlying molecular cues of how HBx-250 Cell Host & Microbe 15, March 12, 2014LINE(1) transcripts induce EMT transi-
tion and nuclear b-catenin translocation.
What are the potential direct and indirect
cellular and even viral binding partners
(proteins, RNAs) for HBx-LINE(1) tran-
scripts? Does the fusion transcript also
bind to nucleosomes and influence the
chromatin microenvironment and cen-
tromere formation as described for
other LINE(1) transcripts (Chueh et al.,
2009)?
From a clinical perspective the pre-
sented data on frequent expression of
HBx-LINE(1) in human HCC and its con-
sequences on patient survival are very
intriguing. Although analysis for HBx-
LINE(1) mRNA expression and correlation
with clinical data need to be confirmed in
other patient cohorts, this finding may be
the starting point to identify subtypes
within HBV-induced HCC with distinctª2014 Elsevier Inc.biological function and presumably also
a different outcome upon therapeutic
intervention.
In conclusion, the study by Lau
et al. (2014) characterizes the biological
function of a class of biologically active,
chimeric RNAs affecting HBV-induced
liver carcinogenesis (Figure 1). At the
same time, the exact mode of action of
HBx-LINE(1) in HCC development needs
to be defined in more detail. Future
studies may characterize additional
viral-human gene fusions and their
biological function—and hopefully pave
the way to exploit these as therapeutic
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